


Atezolizumab IMvigor211

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



Improved QoL



Serious and disabling adverse effects



Other adjustments



Atezolizumab IMvigor211

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE


NEB



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
 Therapeutic Indication: Treatment of patients with locally advanced or metastatic UC after prior platinum-containing ChT
 Experimental Arm: Atezolizumab
 Control Arm: ChT (vinflunine, paclitaxel or docetaxel)

